Johnson & Johnson is acquiring Firefly Bio for $1 billion in cash to add a degrader antibody platform aimed at hard-to-treat ...
Johnson & Johnson JNJ announced that it has entered into a definitive agreement to acquire California-based biotech, Firefly ...
Under the German "individueller Heilversuch" regulatory framework, the patient received an 11-peptide personalized immunotherapy designed without tumor biopsy, using the patient's HLA genotype and ...
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and ...
ADCs have become a core pillar of cancer treatment as increasingly sophisticated design is translating into stronger efficacy ...
BETHESDA, VA, UNITED STATES, June 12, 2026 /EINPresswire.com/ -- Integrating Bioinformatics, Machine Learning, and ...
Acute myeloid leukemia (AML) isn’t the most commonly known cancer. It is, however, one of the deadliest—an awful rare malignancy of the blood and bone marrow whose victims are already older and frail, ...
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio today emphasized the nationwide expansion of ACS ACTS® (Access to Clinical Trials and Support), the American Cancer Society’s program designed to help ...
Cancer arises when the normal controls on cell growth, differentiation and death are subverted. Under physiological conditions, cells proliferate only in response to external stimuli, replicate their ...
A $9.4 million federal grant renewal will help Purdue’s cancer institute support research programs and training initiatives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results